Nightstar's drug for rare vision loss admitted to FDA's gene therapy speedway
In the latest show of regulatory support for gene therapies, Oxford spinout Nightstar Therapeutics just got access to a fairly new “fast-lane” to speed its retinal gene therapy to market.
The London-based company scored an FDA designation called Regenerative Medicine Advanced Therapy, or RMAT, for its Phase III drug NSR-REP1. The therapy is designed to treat choroideremia, a rare genetic condition that causes progressive vision loss, by correcting mutations in the CHM gene.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.